Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Measured Using The Optical Coherence Tomography (OCT) Scanning Laser Ophthalmoscope (SLO) And The Foresee Preferential Hyperacuity Perimeter
Authors not listed
The New York Eye & Ear Infirmary · 2007
Abstract
The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on the strong correlation between VEGF levels in aqueous and vitreous humor and active blood vessel formation. LucentisTM has been shown to maintain or improve vision in wet AMD. Since the treatments do not halt the loss of visual acuity in wet AMD, it is important to accurately measure anatomic response to treatments thereby enhancing the ability to understand patterns of response and predict the necessity for continued therapy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2007). Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Measured Using The Optical Coherence Tomography (OCT) Scanning Laser Ophthalmoscope (SLO) And The Foresee Preferential Hyperacuity Perimeter. <em>The New York Eye & Ear Infirmary</em>. https://clinicaltrials.gov/study/NCT01255774
Vancouver
Anonymous. Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Measured Using The Optical Coherence Tomography (OCT) Scanning Laser Ophthalmoscope (SLO) And The Foresee Preferential Hyperacuity Perimeter. The New York Eye & Ear Infirmary. 2007.
BibTeX
@misc{anon2007Serial,
title = {Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Measured Using The Optical Coherence Tomography (OCT) Scanning Laser Ophthalmoscope (SLO) And The Foresee Preferential Hyperacuity Perimeter},
author = {Anonymous},
journal = {The New York Eye & Ear Infirmary},
year = {2007},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Seoul National University Hospital 2021
Open access · US-GOV
Optical Coherence Tomography Angiography and Microperimetry After Aflibercept in Wet Age-related Macular Degeneration Patients With the Better Baseline Visual Acuity (≥20/40)
Springer eBooks 2008
Citation only
Age‐related Macular Degeneration (AMD)
Unity Health Toronto 2014
Open access · US-GOV
The SHIFT-2 Study: Use of Intravitreal Aflibercept in Wet Age Related Macular Degeneration (AMD) Patients With an Incomplete Response to Routine Ranibizumab Injections
Oxidative Medicine and Cellular Longevity 2018
Open access · CC-BY
Age‐Related Macular Degeneration: New Paradigms for Treatment and Management of AMD
Clinical Interventions in Aging 2006
Open access · OA
Ranibizumab in neovascular age-related macular degeneration
St. Erik Eye Hospital 2006
Open access · US-GOV